Novo Nordisk Reports Sales Growth in 2025
Novo Nordisk announced strong financial results for the first nine months of 2025, showing a 12% increase in sales and a 5% rise in operating profit compared to the previous year.
Sales Performance by Region
- International sales grew by 13% in Danish kroner and at constant exchange rates (CER).
- US sales increased by 12% in kroner and 15% at CER.
Operating Profit and Restructuring Impact
Global operating profit rose 5% in kroner (10% at CER) to DKK 95.9 billion. This figure includes a one-off restructuring charge of about DKK 9 billion, intended to optimize operations for future growth and reinvestment.
Excluding the restructuring cost, operating profit would have grown 15% in kroner and 21% at CER.
Revised Growth Guidance
The company expects full-year sales and operating profit growth in kroner to be 4% and 6% lower, respectively, than at CER. This revision reflects a slowing growth rate for GLP-1 treatments, especially in diabetes and obesity segments.
Therapy Area Sales Growth
- Diabetes and obesity care sales rose 12% to DKK 215.7 billion (15% at CER), led by obesity care treatments which grew 37% in kroner (41% at CER) to DKK 59.9 billion.
- GLP-1 treatments for diabetes increased 7% in kroner (10% at CER).
- Rare disease sales rose by 10% in kroner (13% at CER).
"The revised guidance reflects an anticipated slowdown in the growth of GLP-1 treatments, particularly in the diabetes and obesity segments."
Author's summary: Novo Nordisk showed solid sales and profit growth in early 2025, driven by obesity care and diabetes treatments, but expects slower growth for GLP-1 therapies in the full year.